 BOSTON, May 02, 2022 GLOBE NEWSWIRE -- Praxis Precision Medicines, Inc. NASDAQ: PRAX, a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system CNS disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will provide a corporate update and report financial results for the first quarter 2022 on Monday, May 9, 2022, after the U.S. financial markets close. Management will provide a video update highlighting recent business and pipeline progress in conjunction with a press release. Subsequently, management will host a separate QA session via a live conference call and webcast at 4:30 p.m. ET. 